Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma-Reference-Cited by-同舟云学术

Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma

Published:2019-09 Issue: Volume:119 Page:122-131
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Bastholt Lars^ORCID,Schmidt Henrik,Bjerregaard Jon Kroll,Herrstedt Jørn,Svane Inge Marie

Funder

Bristol-Myers Squibb

Merck MSD

Roche

Novartis

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference26 articles.

1. Nevus size and number are associated with telomere length and represent potential markers of a decreased senescence in vivo;Bataille;Cancer Epidemiol Biomark Prev: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,2007

2. Effect of age on melanoma risk, prognosis and treatment response;Ribero;Acta Derm Venereol,2018

3. Considerations for successful cancer immunotherapy in aged hosts;Hurez;Clin Exp Immunol,2017

4. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis;Nishijima;Cancer Treat Rev,2016

5. Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations;Kugel;Clin Cancer Res: an Official Journal of the American Association for Cancer Research,2018

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regorafenib combined with a PD-1 inhibitor in the second-line setting for unresectable hepatocellular carcinoma in real-world practice;Journal of Gastrointestinal Oncology;2024-02

2. Baseline Values of Circulating IL-6 and TGF-β Might Identify Patients with HNSCC Who Do Not Benefit from Nivolumab Treatment;Cancers;2023-11-02

3. Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma;Current Oncology;2023-09-30

4. Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first‐line anti‐programmed death‐1 monotherapy: A real‐world multicentre observational cohort study;Pigment Cell & Melanoma Research;2023-05-27

5. A joint profile of cytokines and immune cell populations may identify HNSCC patients who benefit from nivolumab treatment. The Gruppo Oncologico Nord-Ovest (GONO) study Nivactor T-2;2023-05-23